Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOUQUET: Biomarker-Driven Therapies in Rare Epithelial Ovarian Tumors
NCT04931342Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2021
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of ipatasertib, cobimetinib, trastuzumab emtansine, atezolizumab, giredestrant in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Roche. Started Oct 2021; status: active, not recruiting.
02
Drugs
ipatasertibcobimetinibtrastuzumab emtansineatezolizumabgiredestrant
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04931342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931342.